Correlogic Assay Is Future Adjunct To Prostate Cancer Detection, NCI Says
This article was originally published in The Gray Sheet
Executive Summary
Proteomic pattern analysis may help reduce the number of unnecessary prostate biopsies, according to the National Cancer Institute
You may also be interested in...
Correlogic Proteome Quest Ovarian Cancer Assay Propels Funding Call On Hill
Sponsors of a House resolution seeking accelerated research and health insurance coverage for a specific type of ovarian cancer test will try to include language from the legislation in the HHS appropriations conference report for fiscal 2003
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.